Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

A novel once-daily drug showed a comparable efficacy and safety profile as the standard-of-care drug in patients with cystic ...

When I first started dating my husband, who has CF, it felt like diving straight into the deep end of the CF world. I was completely overwhelmed at first, but everything changed when I discovered a ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...

Recent research has focused on innovative treatments that target the underlying causes of CF, particularly through the development of CFTR (cystic fibrosis transmembrane conductance regulator ...

Julian Benson and Dermot Bannon tell Claire O'Mahony how Tranquillity House happened. "I’m so thankful that I’m healthy and that I’ve been able to deliver a promise that I made to the Irish people and ...

continues to dominate the cystic fibrosis (CF) treatment market while advancing a promising pipeline of therapies for other serious diseases. The company, which maintains a strong financial health ...